Head to head
Grifols vs Eli Lilly and Co
Side-by-side on the measures that matter, with a plain-English read. Full detail: GRFS · LLY
GRFS
Grifols
7.50-0.27%
1-year price shape — -21% over the period
Quant Rating D · 18/100
vs
LLY
Eli Lilly and Co
1,188.72+2.70%
1-year price shape — +42% over the period
Quant Rating B · 79/100
1-year performance, rebased to 100
Eli Lilly and Co edges it on the scoreable measures. Eli Lilly and Co has the highest Quant Rating (79); Eli Lilly and Co has done best over the past year (+42%); Eli Lilly and Co earns the most per share.
| GRFS | LLY | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - General | Drug Manufacturers - General |
| Last price | 7.50 | 1,188.72 |
| Change today | -0.27% | +2.70% |
| 1-year return | -20.7% | +41.8% |
| Market cap | $5.10B | $1.12T |
| 52-week range | 6.87 – 9.77 | 778.93 – 1,292.65 |
| Valuation | ||
| P/E (TTM) | 10.15 | 39.90 |
| P/E percentile, own 5-yr range | 8th | 6th |
| P/B | 0.82 | 33.03 |
| Dividend yield | 3.71% | 0.54% |
| Profitability & growth | ||
| EPS (TTM) | 0.66 | 22.95 |
| Net profit (TTM) | $449.86M | $21.60B |
| Revenue (TTM) | $7.42B | $79.67B |
| Revenue growth (YoY) | -0.9% | +47.7% |
| Gross margin | 37.0% | 83.4% |
| Operating margin | 16.2% | 49.7% |
| Net margin | 6.1% | 33.5% |
| Free cash flow (TTM) | $643.54M | $13.56B |
| Ownership & sentiment | ||
| Institutional ownership | 70.2% | 79.5% |
| Insider activity (12mo) | 0 buy / 0 sell | 37 buy / 13 sell |
| Short interest (% of float) | 0.5% | 0.8% |
| Analyst consensus | -- | 91% buy / 5% hold / 5% sell (22) |
| Analyst price target | -- | $1,381 (+16%) |
| StockVane view | ||
| StockVane Quant Rating | D (18) | B (79) |
| Company | ||
| Employees | 25,247 | 50,000 |
| Founded | 1909 | 1876 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.